Inventor · disambiguated record
Roger Leger
Also filed as: LEGER ROGER · LEGER ROGER J · LEGER ROGER JOSEPH
15 granted patents·11 pending applications·495 citations·filing 1994–2023
94Inventor score
Files withCONJUCHEM BIOTECHNOLOGIES INC6MICROCIDE PHARMACEUTICALS INC5CONJUCHEM INC2ESSENTIAL THERAPEUTICS INC2THRASOS THERAPEUTICS INC2
Top patents by PatentIndex Score
26 records- 0196US6399629B1Efflux pump inhibitorsMICROCIDE PHARMACEUTICALS INC·Filed 1998·Granted Jun 4, 2002·131 cites·59 claims
- 0294US7601691B2Anti-obesity agentsCONJUCHEM BIOTECHNOLOGIES INC·Filed 2005·Granted Oct 13, 2009·27 cites·39 claims
- 0393US7112567B2Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disordersCONJUCHEM INC·Filed 2002·Granted Sep 26, 2006·40 cites·8 claims
- 0492US6436980B1Peptidomimetic efflux pump inhibitorsESSENTIAL THERAPEUTICS INC·Filed 2000·Granted Aug 20, 2002·59 cites·19 claims
- 0590US7737251B2Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disordersCONJUCHEM BIOTECHNOLOGIES INC·Filed 2005·Granted Jun 15, 2010·9 cites·52 claims
- 0687US7268113B2Long lasting growth hormone releasing factor derivativesCONJUCHEM BIOTECHNOLOGIES INC·Filed 2002·Granted Sep 11, 2007·44 cites·20 claims
- 0784US6114310AEfflux pump inhibitorsMICROCIDE PHARMACEUTICALS INC·Filed 1998·Granted Sep 5, 2000·67 cites·33 claims
- 0882US9611297B1Compositions and methods for the treatment of cast nephropathy and related conditionsTHRASOS THERAPEUTICS INC·Filed 2016·Granted Apr 4, 2017·7 cites·3 claims
- 0970US6245746B1Efflux pump inhibitorsMICROCIDE PHARMACEUTICALS INC·Filed 1998·Granted Jun 12, 2001·35 cites·35 claims
- 1069US7906482B2Anti-obesity agentsADVANCED DIAGNOSTICS AND DISCOVERY·Filed 2007·Granted Mar 15, 2011·1 cites·48 claims
- 1168US5507149ANonporous liquid impermeable cryogenic barrierFiled 1994·Granted Apr 16, 1996·31 cites·19 claims
- 1265US6204279B1Peptidomimetic efflux pump inhibitorsMICROCIDE PHARMACEUTICALS INC·Filed 1998·Granted Mar 20, 2001·25 cites·22 claims
- 1365US2024166990A1Methods and compositions for increasing protein expression in genetically engineered bacteriaAZITRA INC·Filed 2023·Application pending·0 cites
- 1463US2009275506A1Long lasting natriuretic peptide derivativesCONJUCHEM BIOTECHNOLOGIES INC·Filed 2008·Application pending·0 cites
- 1563US2009312259A1Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disordersCONJUCHEM BIOTECHNOLOGIES INC·Filed 2009·Application pending·0 cites
- 1661US2008199532A1Long Lasting Natriuretic Peptide DerivativesCONJUCHEM BIOTECHNOLOGIES INC·Filed 2007·Application pending·0 cites
- 1756US6455268B1Hydrolytic enzyme substrates and assay methodICONIX PHARM INC·Filed 2000·Granted Sep 24, 2002·13 cites·17 claims
- 1854US2005176641A1Long lasting natriuretic peptide derivativesCONJUCHEM INC·Filed 2005·Application pending·0 cites
- 1953US2004266673A1Long lasting natriuretic peptide derivativesFiled 2003·Application pending·0 cites
- 2045US2008146562A1Halogenated quinazolinyl nitrofurans as antibacterial agentsULYSSES PHARMACEUTICAL PRODUCT·Filed 2007·Application pending·0 cites
- 2145US2006241019A1Long lasting insulin derivatives and methods thereofBRIDON DOMINIQUE P·Filed 2004·Application pending·0 cites
- 2240US2018057534A1Compositions and methods for the treatment of cast nephropathy and related conditionsTHRASOS THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 2339US6228842B1Pacidamycins produced by Streptomyces coeruleorubidusMICROCIDE PHARMACEUTICALS INC·Filed 1998·Granted May 8, 2001·2 cites·15 claims
- 2438US2016137714A1Peptides with enhanced stability and their use in methods for treating diseasesTHRASOS INNOVATION INC·Filed 2015·Application pending·0 cites
- 2536US6482921B1Uridyl peptide antibiotic (UPA) derivatives, their synthesis and useESSENTIAL THERAPEUTICS INC·Filed 1999·Granted Nov 19, 2002·4 cites·31 claims
- 2634US2003151418A1Low voltage circuit testerFiled 2002·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →